Stem cell transplantation is the only curative approach to the treatment of Wiskott-Aldrich syndrome. However, using grafts from partially matched unrelated donors is associated with increased risk of graft rejection and graft-versus-host disease. In an attempt to prevent these problems, a 6-year-old boy with WiskottAldrich syndrome lacking a suitable family donor, was transplanted with large numbers of unrelated highly purified CD34
fied supportive therapy, such as prophylactic administration of antibiotics and immunoglobulins, use of platelet transfusions and splenectomy, the survival of these patients remains poor. 5, 6 The only curative approach is allogeneic stem cell transplantation. 7, 8 Most successful transplants utilized HLA-identical sibling donors. [9] [10] [11] [12] [13] The results of unrelated matched or mismatched donor transplantations are associated with an increased risk of graft rejection and graft-versus-host disease (GVHD). [14] [15] [16] In an attempt to overcome these limitations a 'megadose' of highly purified CD34 ϩ peripheral blood stem cells (PBSC) from an unrelated C-locus mismatched donor was used in this patient. This report details the clinical outcome, as well as the hematopoietic and immunologic reconstitution and follow-up after this kind of unrelated peripheral blood stem cell transplant in a patient with WAS.
Case report
The diagnosis of WAS was established at the age of 10 months by the presence of thrombocytopenia, abnormal small 'microplatelets', eczema and immune deficiency. At the age of 13 months, the patient was splenectomized due to a massive intestinal bleeding refractory to platelet transfusions. This intervention resulted in normal platelet counts for 4 years. The boy was treated with 7-s immunoglobulin infusions (1 g/kg body weight) every 3 to 6 months, and received oral decontamination consisting of trimetoprimsulfamethoxazole (3 mg/kg/day) for prophylaxis of Pneumocystis carinii for 4 days each week, penicillin-G and fluconazole. Despite this treatment the patient experienced several severe bacterial infections prior to and after splenectomy. At the age of 5 years platelet counts decreased again (р20 000/l) and a banal head injury resulted in a massive bilateral orbital hematoma (Figure 1 ). At this time diagnosis of WAS was confirmed by the deletion of the Cnucleotide of exon 10 (position 1065) which was found after amplification of exon 1-12 of the WASP-gene by polymerase chain reaction (PCR) followed by direct sequencing of the PCR products.
In the absence of an HLA-identical family donor, an international search for potential unrelated donors was per- formed by the Austrian Bone Marrow Donor Registry and a suitable donor was found by the Deutsche Knochenmarsspenderdatei (DKMS, Tübingen, Germany). The donor was mismatched at one HLA-C locus (patient: A 1,3; B 38,60; C w2; DRB1 0801, 1301; DRB3 0101; DQB1 0402, 0603; donor: A 1,3; B 38,60; C w3; DRB1 0801,1301; DRB3 0101; DQB1 0402, 0603). After obtaining informed consent the donor cells were mobilized with G-CSF (5 g/kg body weight/day) for 5 days.
A single leukapheresis was performed and yielded 9.04 ϫ 10 10 nucleated cells (NC) with 7. . The patient received 24.5 ϫ 10 6 CD34 ϩ cells/kg body weight together with 1 ϫ 10 4 CD3 ϩ cells/kg/body weight after conditioning with busulfan (4 mg/kg body weight ϫ 4), cyclophosphamide (50 mg/kg body weight ϫ 4) and antithymocyte globulin (ATG, horse; Sero Merieux, Vienna, Austria) (20 mg/kg body weight ϫ 3). He was given G-CSF 5 g/kg/day subcutaneously starting at day ϩ4 and erythropoietin (EPO) at a dosage of 150 IU/day subcutaneously until white blood cell counts stabilized at у5 ϫ 10 9 /l and hemoglobin levels у10 g/dl without erythrocyte transfusions for 10 consecutive days.
The boy showed complete hematological reconstitution of donor origin with ANC у0.5 ϫ 10 9 /l on day ϩ8, platelets у20 ϫ 10 9 /l on day ϩ11 and 0.9% reticulocytes on day ϩ11. A measurable number of circulating lymphocytes appeared 1 month after transplantation. The majority of these early lymphocytes were analyzed as CD56 + /CD16 ϩ natural killer (NK) cells. The patient showed a constant increase in T lymphocytes (CD3 ϩ ) and also an impressive rise in B lymphocytes (CD19 ϩ ) within 9 months after transplantation. T lymphocytes showed a normal proliferative response to polyclonal activators (phytohemagglutinin, concanavalin A, pokeweed mitogen) within 12 months after transplantation (Table 1) . 17 Repeated chimerism analysis of peripheral blood revealed permanent 100% donor hematopoiesis and the underlying gene defect (deletion of the Cnucleotide of exon 10, position 1065) could not be detected in the peripheral blood or the bone marrow cells. Eczema disappeared 2 weeks after starting conditioning chemotherapy, but reappeared within 5 weeks after transplantation due to an allergic reaction against yeast and milk protein. This was proven by elevation of serum levels of IgE up to 1386 U/ml, by radio-immunosorbent test (RIST), radioallergosorbent test (RAST) and histological examination of repeated skin biopsies and disappeared after a milk-free diet. As of 1 May 2000, the patient is alive and well without any further treatment for 25 months.
Discussion
Despite intensive supportive care such as splenectomy, infusion of immunoglobulins, platelet transfusions and prophylactic administration of broad-spectrum antibiotics, the only curative approach in patients with WAS is allogeneic stem cell transplantation. [7] [8] [9] [10] [11] [12] [13] An HLA-identical sibling graft is the preferred stem cell source, whereas the outcome with HLA-non-identical bone marrow or peripheral blood stem cells with or without T cell depletion is rather poor because of graft rejection and acute/chronic GvHD.
14-16 Therefore Ozsahin et al 11 concluded that transplants from partially incompatible donors should be restricted to patients with severe complications of WAS. On the other hand, patients should be transplanted in optimum condition, before severe complications from the underlying disease develop. In our patient the transfusion of large numbers ('megadose') of highly purified T cell-depleted CD34 ϩ stem cells was used, assuming that megadoses of CD34 ϩ cells might overcome the HLA-mismatch in the unrelated donor setting and abrogate resistance to engraftment. [18] [19] [20] [21] Magnetic cell sorting (MACS) of peripheral blood CD34 ϩ cells proved to be an excellent procedure recovering sufficient numbers of stem cells with high purity and low T cell contamination. 22, 23 The patient showed rapid and sustained hematological engraftment with complete immunological reconstitution within 9 months and did not receive prophylactic immunosuppressive treatment.
To our knowledge this is the first report of the clinical 237 Table 1 Immunological reconstitution outcome, hematopoietic and immunologic reconstitution and follow-up of a child with WAS who underwent transplantation with unrelated highly purified CD34 ϩ cells mismatched at one C-locus. The favorable outcome in this patient might encourage further investigation of the role of using 'megadoses' of unrelated matched or mismatched CD34
ϩ -selected peripheral blood stem cells in patients with WAS at an earlier stage of disease before severe and lifethreatening complications might interfere negatively with the transplantation outcome.
